about
Imputation and subset based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesTargeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma CellsGenome-wide association study identifies two susceptibility loci for osteosarcomaNucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with OsteosarcomaPreclinical validation of Aurora kinases-targeting drugs in osteosarcoma.Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.CD99 polymorphisms significantly influence the probability to develop Ewing sarcoma in earlier age and patient disease progression.Emerging drugs for high-grade osteosarcoma.Sensitive mRNA detection by fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification.Advances in emerging drugs for osteosarcoma.Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance.Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.The pharmacogenomics of osteosarcoma.Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines.P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2.Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells.Induction of p21 mRNA synthesis after short-wavelength UV light visualized in individual cells by RNA FISH.Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation--sign of tumour cell revertance?Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone.Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma.Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors.Unequivocal identification of disseminated tumor cells in the bone marrow by combining immunological and genetic approaches--functional and prognostic information.Molecular Cytogenetics in Ewing Tumors: Diagnostic and Prognostic Information.Fine-mapping of cytogenetically undetectable EWS/ERG fusions on DNA fibers of Ewing tumors.The EWS protein is dispensable for Ewing tumor growth.Quality assessment of genetic markers used for therapy stratification.
P50
Q23924183-6C2EDBD2-B800-495D-9D25-DE9D202C669CQ24170413-F2EFF419-C48B-4441-A6DE-E788E071034FQ28554501-3B1019AA-17F7-4D37-A2AE-60EA0B1D1E43Q28659642-C2D900C1-4BED-4D86-AA75-92B9B7677968Q33985880-7D8460AB-E53B-4BF6-97BB-3F434B3F8086Q36029709-942A493C-661A-46F9-9493-84B9987A2079Q37323073-BB3DAD48-3D43-4E25-B6C0-7BEB8D8EF62EQ37641721-A7B5D38C-E1B5-4E21-AD2B-44CF09AD7273Q37718471-91444479-5258-418E-A761-443696868499Q37778400-BDE95665-A9CA-486C-8A5F-A2FCE41A24DDQ38332459-F774BD7C-7FE4-43C7-B736-06EE65B63278Q38506118-EE511CDA-B95A-4258-851B-7B32D0F5667CQ38533459-C751018B-A45E-4AEC-923D-24CB5DE3CA34Q38734066-FB8DE378-E7AE-4FE2-AEC8-58788D9B2C29Q38759270-C00DBB2F-B9D3-45F7-92DE-7710818222D2Q38775062-B5AA233E-5331-4F0D-8558-2C44141952EFQ38791215-ED9049FA-1146-4BA1-9536-C4E1182B9DEAQ38809116-D02EF461-DBA0-4B21-B46F-89AAA7B773A6Q38848413-CFC72445-CD8D-45DF-914F-397208392270Q38959358-A70F2D18-2749-4DB3-A772-DA81F26CF03DQ39902204-FAC21A75-B10B-4B56-AF75-DAB654F6C643Q39956747-E5442A17-DE2E-4245-9B23-8D26CBA5936CQ39995579-69953EA0-DD13-467E-9C9F-6E51798F1C50Q40354019-012DBB2D-33B3-450C-A7D2-910AFB1C7B56Q40378150-573ECD62-36D8-4474-9805-F51F5203B874Q40417879-C868CDCF-9986-46E5-940D-28890D566695Q40606723-EF497364-FAAF-41F5-91D1-505C929C167BQ40762557-CE5E9BE4-BB25-4698-9508-211015C9ABCAQ42817425-8EDEF01D-9500-43F0-8D49-7A4B247A4CFFQ44634672-E0EB75C9-38DD-4BDC-9B20-91DA261F624EQ45125767-A9BFDB18-D552-421E-B0BE-06867D76AD7CQ46431085-436689FD-84E9-449E-A9C7-0DF280288048Q46904091-5F19CD23-7E0F-427A-B23D-A8F448C304E2Q47773300-A0647EFC-5E0E-4F19-8E2F-EC8DCD44F919Q50756853-3FCFE87C-005C-4B04-A5BE-5424C48328B2Q50758832-FFE4688A-0D64-431D-ADEA-E4BF54FA0ACCQ50759345-B1E2E892-F23B-48DD-835D-8DE54A2949D9Q50759418-7E7903D0-BFD5-49AF-A647-291357801F83Q50759482-B0232B47-3C9A-4627-824F-B6649B79F024Q51024497-F4A86CA7-A1E4-4192-9CA7-702FC6889F6C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudia Maria Hattinger
@ast
Claudia Maria Hattinger
@en
Claudia Maria Hattinger
@es
Claudia Maria Hattinger
@nl
Claudia Maria Hattinger
@sl
type
label
Claudia Maria Hattinger
@ast
Claudia Maria Hattinger
@en
Claudia Maria Hattinger
@es
Claudia Maria Hattinger
@nl
Claudia Maria Hattinger
@sl
prefLabel
Claudia Maria Hattinger
@ast
Claudia Maria Hattinger
@en
Claudia Maria Hattinger
@es
Claudia Maria Hattinger
@nl
Claudia Maria Hattinger
@sl
P1053
Q-1212-2016
P106
P21
P31
P3829
P496
0000-0002-9316-5095